Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

By R. Motzer, Thomas E. Hutson, H. Glen, M. Michaelson, A. Molina, T. Eisen, J. Jassem, J. Zolnierek, J. Maroto, B. Mellado and 7 more. The Lancet Oncology, 2015

826 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/5b34b81d05b8dbf09b0b2b238791fb03eac135ff

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Charles Swanton
2. Gautam Sethi
3. Huanhuan Chen
4. Li-li Zheng
5. Zhenling Liu
6. Li-Ping Sun
7. Lei Shi
8. D. Fruman

In Pulmonary and Respiratory Medicine

1. Charles Swanton

Citations in the corpus

• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Obviously, availability of these two drugs is still heterogenous, and several situations should be differentiated:  If only nivolumab is available, it should be recommended  If both nivolumab and cabozantinib are available, either drug is recommended  The combination of lenvatinib and everolimus ”
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “ The combination of lenvatinib and everolimus showed PFS and OS benefit over everolimus based on a randomised study of 150 patients [53] and is FDA and D ow naded rom http/academ ic.”
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “tion of everolimus and lenvatinib in RCC patients are constipation (37%) and diarrhea (20%) [4, 292].”
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, methodology): “Lenvatinib and everolimus were approved as a 111 combined treatment for advanced renal cell carcinoma following 1 prior anti-angiogenic therapy.(17) In a 112”
• Renal cell carcinoma (2017, background): “ The combination of lenvatinib and everolimus showed PFS and OS benefit over everolimus based on a randomised study of 150 patients [53] and is FDA and D ow naded rom http/academ ic.”
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “In 2016, the combination of lenvatinib with mTOR inhibitor everolimus (Table 1) was approved for advanced RCC (NCT01136733).(436,437) In 2021, the combination of lenvatinib with pembrolizumab (PD-1 antibody) became the first-line treatment for adult patients with advanced RCC due to the significantl”